Adverse Effects Associated with ChAdOx1-S Vaccination Against SARS-COV-2 In People Over 18. Systematic Review
DOI:
https://doi.org/10.18041/2390-0512/biociencias.2.12324Keywords:
Coronavirus, Vaccine, Thrombocytopenia, Thrombosis, Adverse effects, ComorbiditiesAbstract
Introduction: In 2020 the world faced a pandemic in which the SARS-COV-2 virus was the cause of this global crisis, during this pandemic there were effects in all areas. In response to this major problem, several vaccines were hastily developed in response to the health emergency.
Among the vaccines that were developed during the SARS-COV-2 pandemic is the ChAdOx1-S vaccine, which was recently withdrawn from the market generating concern about the cause of its exit, which led to this systematic review, which aims to identify adverse effects associated with ChAdOx1-S vaccination against SARS-COV-2 in people over 18 years of age.
It also seeks to find the possible causes of adverse effects attributable to the population vaccinated with ChAdOx1-S.
Methods: A systematic review was conducted from June 20 to July 19, 2024 using the databases PubMed, SCOPUS, SciELO and ClinicalKey, After the search and selection using the STROBE method guidelines, 5 observational studies were included that evaluated the population over 18 years of age vaccinated with ChAdOx1-S and showed adverse effects.
Results: The most commonly reported adverse effects are mild symptoms, which include local pain, redness and swelling that occur in the majority of vaccinated people, mainly in young adults and with a prevalence in the female gender.
Conclusion: There is sufficient evidence to establish a relationship between adverse effects and the application of ChAdOx1-S vaccine, with slightly higher susceptibility than other vaccines.
Downloads
References
1. Santos-López, Gerardo, et al. “SARS-CoV-2: Generalidades, Origen Y Avances En El Tratamiento | Gaceta Médica de México.” Www.gacetamedicademexico.com, 2020, www.gacetamedicademexico.com/frame_eng.php?id=550.
2. Laiter, Yael Zonenzsain. “Las Vacunas Contra El Covid-19: Dos Dilemas Éticos a Considerar.” Revista de Medicina Y Ética, vol. 32, no. 1, 4 Jan. 2021, pp. 215–231, revistas.anahuac.mx/bioetica/article/view/474/330, https://doi.org/10.36105/mye.2021v32n1.06.
3. Amanat F, Krammer F. SARS-CoV-2 vaccines: Status report. Immunity [Internet]. 2020;52(4):583–9. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S1074761320301205
4. FDA. FDA approves first COVID-19 vaccine [Internet]. U.S. Food and Drug Administration. FDA; 2024 [citado el 26 de junio de 2024]. Disponible en: https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine
5. Pierson B. Kansas accuses Pfizer of misleading public about COVID vaccine in lawsuit [Internet]. Reuters. 17 de Junio 2024 [citado el 5 de julio de 2024]. Disponible en: https://www.reuters.com/legal/kansas-accuses-pfizer-misleading-public-about-covid-vaccine-lawsuit-2024-06-17/
6. Department of Health, Social Care. Second COVID-19 vaccine authorised by medicines regulator [Internet]. Gov.uk. 2020 [citado el 30 de junio de 2024]. Disponible en: https://www.gov.uk/government/news/second-covid-19-vaccine-authorised-by-medicines-regulator
7. Gómez-Roldós A, González-Sánchez M, Vales-Montero M, Vázquez-Alen P, Fernández-Bullido Y, Iglesias-Mohedano AM, et al. Fatal intracerebral haemorrhage associated with thrombosis with thrombocytopenia syndrome after ChAdOx1-S vaccine. Rev Neurol [Internet]. 2022;75(7):199–202. Disponible en: http://dx.doi.org/10.33588/rn.7507.2021323
8. Chemaitelly H, Akhtar N, Jerdi SA, Kamran S, Joseph S, Morgan D, et al. Association between COVID-19 vaccination and stroke: a nationwide case-control study in Qatar. Int J Infect Dis [Internet]. 2024;145:107095. Disponible en: http://dx.doi.org/10.1016/j.ijid.2024.107095
9. Eterafi M, Fouladi N, Golizadeh M, Shaker H, Matin S, Safarzadeh E. Reported side-effects following Oxford/AstraZeneca COVID-19 vaccine in the north-west province, Iran: A cross-sectional study. PLoS One [Internet]. 2024;19(1):e0296669. Disponible en: http://dx.doi.org/10.1371/journal.pone.0296669
10. Watanabe S, Tamura Y, Oba K, Kitayama S, Sato M, Kodera R, et al. Hypopituitarism with secondary adrenocortical insufficiency and arginine vasopressin deficiency due to hypophysitis after COVID-19 vaccination: a case report. BMC Endocr Disord [Internet]. 2024;24(1):71. Disponible en: http://dx.doi.org/10.1186/s12902-024-01582-9
11. Rolfes L, Härmark L, Kant A, van Balveren L, Hilgersom W, van Hunsel F. COVID-19 vaccine reactogenicity - A cohort event monitoring study in the Netherlands using patient reported outcomes. Vaccine [Internet]. 2022;40(7):970–6. Disponible en: http://dx.doi.org/10.1016/j.vaccine.2022.01.013
12. Watson RA, Ye W, Taylor CA, Jungkurth E, Cooper R, Tong O, et al. Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination. J Immunother Cancer [Internet]. 2024;12(4). Disponible en: http://dx.doi.org/10.1136/jitc-2023-008151
13. Xiang Y, Feng Y, Qiu J, Zhang R, So H-C. Association of COVID-19 vaccination with risks of hospitalization due to cardiovascular and other diseases: A study using data from the UK Biobank. Int J Infect Dis [Internet]. 2024;145:107080. Disponible en: http://dx.doi.org/10.1016/j.ijid.2024.107080
14. Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med [Internet]. 2021;28(2):410–22. Disponible en: http://dx.doi.org/10.1038/s41591-021-01630-0
15. Holwerda MR, Hoeve CE, Huiberts AJ, den Hartog G, de Melker HE, van den Hof S, et al. Association between adverse events after COVID-19 vaccination and anti-SARS-CoV-2 antibody concentrations, the Netherlands, May 2021 to November 2022: a population-based prospective cohort study. Euro Surveill [Internet]. 2024;29(25). Disponible en: http://dx.doi.org/10.2807/1560-7917.ES.2024.29.25.2300585
16. Santin AD. VITT after ChAdOx1 nCoV-19 vaccination. New England Journal of Medicine [Internet]. 2021;385(23):2202–5. Disponible en: https://www.nejm.org/doi/full/10.1056/NEJMc2111026
17. Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A, Mohammadi P, Nomovi M, Mowla A. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review. J Neurol Sci [Internet]. 2021;428:117607. Disponible en: http://dx.doi.org/10.1016/j.jns.2021.117607
18. Alemayehu A, Demissie A, Yusuf M, Abdullahi Y, Abdulwehab R, Oljira L, et al. COVID-19 vaccine side effect: age and gender disparity in adverse effects following the first dose of AstraZeneca COVID-19 vaccine among the vaccinated population in Eastern Ethiopia: a community-based study. SAGE Open Med [Internet]. 2022;10. Disponible en: http://dx.doi.org/10.1177/20503121221108616
19. Pimentel MAF, Shaikh M, Al Safi M, Naqvi Y, Khan S. COVID-19 vaccination and major cardiovascular and haematological adverse events in Abu Dhabi: retrospective cohort study. Nat Commun [Internet]. 2024;15(1):5490. Disponible en: http://dx.doi.org/10.1038/s41467-024-49744-6
20. Robbins R. AstraZeneca retira su vacuna contra la covid en todo el mundo por baja demanda, afirma la farmacéutica. The New York times [Internet]. el 9 de mayo de 2024 [citado el 10 de julio 2024]; Disponible en: https://www.nytimes.com/es/2024/05/09/espanol/astrazeneca-vacuna-covid.html
21. Amer, Samar A., et al. “Exploring the Reported Adverse Effects of COVID-19 Vaccines among Vaccinated Arab Populations: A Multi-National Survey Study.” Scientific Reports, vol. 14, no. 1, 27 Feb. 2024, p. 4785, www.nature.com/articles/s41598-024-54886-0, https://doi.org/10.1038/s41598-024-54886-0.
22. Pottegård, Anton, et al. “Arterial Events, Venous Thromboembolism, Thrombocytopenia, and Bleeding after Vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: Population Based Cohort Study.” BMJ, 5 May 2021, p. n1114, www.bmj.com/content/bmj/373/bmj.n1114.full.pdf, https://doi.org/10.1136/bmj.n1114.
23. Holder, Josh. “Tracking Coronavirus Vaccinations around the World.” The New York Times, 13 Mar. 2023, www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html.
24. World Health Organization. “Interim Recommendations for Use of the ChAdOx1-S [Recombinant] Vaccine against COVID-19 (AstraZeneca COVID-19 Vaccine AZD1222 VaxzevriaTM, SII COVISHIELDTM): Interim Guidance, First Issued 10 February 2021, Updated 21 April 2021, Updated 30 July 2021, Latest Update 15 March 2022.” Who.int, 2022, iris.who.int/handle/10665/352466, https://doi.org/WHO/2019-nCoV/vaccines/SAGE_recommendation/AZD1222/2022.1.
25. Lamprinou, Malamatenia, et al. “COVID-19 Vaccines Adverse Events: Potential Molecular Mechanisms.” Immunologic Research, 6 Jan. 2023, https://doi.org/10.1007/s12026-023-09357-5.
26. George, Tom, and Mark F. Brady. “Ethylenediaminetetraacetic Acid (EDTA).” PubMed, StatPearls Publishing, 26 de Junio de 2023, www.ncbi.nlm.nih.gov/books/NBK565883/.
27. Borgsteede, Sander D., et al. “Other Excipients than PEG Might Cause Serious Hypersensitivity Reactions in COVID‐19 Vaccines.” Allergy, vol. 76, no. 6, June 2021, pp. 1941–1942, https://doi.org/10.1111/all.14774.
28. Cabanillas, Beatriz, and Natalija Novak. “Allergy to COVID-19 Vaccines: A Current Update.” Allergology International, Apr. 2021, https://doi.org/10.1016/j.alit.2021.04.003. Accessed 6 May 2021.
29. Makris, Michael, and Sue Pavord. “Most Cases of Thrombosis and Thrombocytopenia Syndrome (TTS) Post ChAdOx-1 NCov-19 Are Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT).” The Lancet Regional Health - Europe, vol. 12, Jan. 2022, p. 100274, https://doi.org/10.1016/j.lanepe.2021.100274. Accessed 3 Dec. 2021.
30. Marietta, Marco, et al. “Potential Mechanisms of Vaccine-Induced Thrombosis.” European Journal of Internal Medicine, vol. 105, 1 Nov. 2022, pp. 1–7, www.ncbi.nlm.nih.gov/pmc/articles/PMC9359676/, https://doi.org/10.1016/j.ejim.2022.08.002. Accessed 6 Nov. 2022.
31. Hsiao P-J, Wu K-L, Chen Y-C, Chen Y-L, Wang R-L, Wu K-A, et al. The role of anti-platelet factor 4 antibodies and platelet activation tests in patients with vaccine-induced immune thrombotic thrombocytopenia: Brief report on a comparison of the laboratory diagnosis and literature review. Clin Chim Acta [Internet]. 2022;529:42–5. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0009898122000468
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Biociencias
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
